New drug cocktail shows promise for resistant blood cancer
NCT ID NCT05199051
First seen Jan 09, 2026 · Last updated May 15, 2026 · Updated 21 times
Summary
This study is testing a combination of two drugs, gemtuzumab ozogamicin (GO) and gilteritinib, in adults with a type of acute myeloid leukemia (AML) that has come back or not responded to treatment. The leukemia must have a specific genetic change called FLT3 mutation. The goal is to see if adding gilteritinib to the standard GO-chemotherapy platform is safe and helps patients live longer without the cancer returning. About 19 participants are being treated in this early-phase trial across France.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHMS de Chambery
Chambéry, France
-
CHRU Nancy
Nancy, France
-
CHU Bordeaux
Bordeaux, France
-
CHU Limoges
Limoges, France
-
CHU d'Amiens
Amiens, France
-
CHU d'Angers
Angers, France
-
CHU de Caen
Caen, France
-
Centre Henri Becquerel
Rouen, France
-
Centre Hospitalier Universitaire de Nice
Nice, France
-
Centre Hospitalier de Versailles
Versailles, France
-
HIA Percy
Clamart, France
-
Hôpital Saint Louis
Paris, France
Conditions
Explore the condition pages connected to this study.